Table 1 Clinical trials evaluating axillary lymph node dissection in clinically node-negative patients. Summary of trials evaluating the role of axillary lymph node dissection in patients presenting with no clinical evidence of axillary lymphadenopathy
From: Targeting and limiting surgery for patients with node-positive breast cancer
Trial | Breast surgery | Number of positive sentinel lymph nodes allowed | Randomization groups | Number | 5-year locoregional recurrence | 5-years overall survival |
|---|---|---|---|---|---|---|
BCT | 1-2 | ALND | 420 | 1.6 % | 91.9 % | |
No ALND a | 436 | 3.1 % | 92.5 % | |||
AMAROS [5] | BCT or Mastectomy | No limit | ALND | 744 | Axillary recurrence 0.43 % | 93.3 % |
Axillary RT | 682 | 1.19 % | 92.5 % | |||
IBCSG 23-01 [6] | BCT or Mastectomy | No limit- all metastases had to be ≤2 mm | ALND | 464 | 2.4 % | 97.6 % |
No ALND a | 467 | 2.8 % | 97.5 % |